A phase I/II, multicentre clinical study of ZD1839 (Iressa (TM)) in combination with capecitabine (Xeloda) in subjects with advanced colorectal carcinoma after failure of first-line chemotherapy.
Latest Information Update: 18 May 2009
At a glance
- Drugs Gefitinib (Primary) ; Capecitabine
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 16 Dec 2007 Status changed from in progress to completed.
- 24 Mar 2006 New trial record.